Neurocrine Biosciences Inc. announced that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
144.6 USD | -1.90% | -1.68% | +9.78% |
07-09 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
07-03 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.78% | 14.84B | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
-46.10% | 14.79B | |
+52.34% | 14.08B | |
+143.76% | 12.57B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences Inc. Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia